Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)

Predicting Antitumor Activity of Anthrapyrazole Derivatives using Advanced Machine Learning Techniques

BACKGROUND

Anthrapyrazoles are a new class of antitumor agents and successors to anthracyclines possessing a broad range of antitumor activity in various model tumors.

OBJECTIVES

The present study introduces novel QSAR models for the prediction of antitumor activity of anthrapyrazole analogues.

METHODS

The predictive performance of four machine learning algorithms, namely artificial neural networks, boosted trees, multivariate adaptive regression splines, and random forest, was studied in terms of variation of the observed and predicted data, internal validation, predictability, precision, and accuracy.

RESULTS

ANN and boosted trees algorithms met the validation criteria. It means that these procedures may be able to forecast the anticancer effects of the anthrapyrazoles studied. Evaluation of validation metrics, calculated for each approach, indicated the artificial neural network (ANN) procedure as the algorithm of choice, especially with regard to the obtained predictability as well as the lowest value of mean absolute error. The designed multilayer perceptron (MLP)-15-7-1 network displayed a high correlation between the predicted and the experimental pIC50 value for the training, test, and validation set. A conducted sensitivity analysis enabled an indication of the most important structural features of the studied activity.

CONCLUSION

The ANN strategy combines topographical and topological information and can be used for the design and development of novel anthrapyrazole analogues as anticancer molecules.

Indazole as a Privileged Scaffold: The Derivatives and their Therapeutic Applications

BACKGROUND

Heterocyclic compounds, also called heterocycles, are a major class of organic chemical compound that plays a vital role in the metabolism of all living cells. The heterocyclic compound, indazole, has attracted more attention in recent years and is widely present in numerous commercially available drugs. Indazole-containing derivatives, representing one of the most important heterocycles in drug molecules, are endowed with a broad range of biological properties.

METHODS

A literature search was conducted in PubMed, Google Scholar and Web of Science regarding articles related to indazole and its therapeutic application.

RESULTS

The mechanism and structure-activity relationship of indazole and its derivatives were described. Based on their versatile biological activities, the compounds were divided into six groups: anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour. At least 43 indazole-based therapeutic agents were found to be used in clinical application or clinical trials.

CONCLUSION

This review is a guide for pharmacologists who are in search of valid preclinical/clinical drug compounds where the progress of approved marketed drugs containing indazole scaffold is examined from 1966 to the present day. Future direction involves more diverse bioactive moieties with indazole scaffold and greater insights into its mechanism.

New cytotoxic agents: a review of the literature

The goal of treatment for patients with advanced cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction of many cytotoxic agents during the past decade, only modest improvement in survival has been achieved. In order to urgently improve these situations, new cytotoxic agents as well as molecular-targeted agents are now under investigation. In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of the new cytotoxic agents.